Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Long-Term Debt Repayments (2016 - 2018)

ImmunityBio (IBRX) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $142000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Long-Term Debt Repayments rose 121.88% to $142000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $477000.0, a 97.61% decrease, with the full-year FY2025 number at $1.1 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $142000.0 for Q4 2018 at ImmunityBio, up from $137000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $14.9 million in Q3 2017 to a low of $1000.0 in Q4 2014.
  • A 5-year average of $1.5 million and a median of $64500.0 in 2017 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: soared 149380.0% in 2017, then crashed 99.08% in 2018.
  • ImmunityBio's Long-Term Debt Repayments stood at $1000.0 in 2014, then surged by 100.0% to $2000.0 in 2015, then skyrocketed by 1000.0% to $22000.0 in 2016, then surged by 190.91% to $64000.0 in 2017, then surged by 121.88% to $142000.0 in 2018.
  • Per Business Quant, the three most recent readings for IBRX's Long-Term Debt Repayments are $142000.0 (Q4 2018), $137000.0 (Q3 2018), and $133000.0 (Q2 2018).